Reducing Sedentary Behavior to Improve Sleep: an Ancillary Study to the RESET BP Clinical Trial (RESET-SLEEP)

Using a multi-method sleep assessment approach, the purpose of this study is to examine the bidirectional relationship between sleep and sedentary behavior in the context of a randomized trial investigating the impact of sedentary behavior reduction on blood pressure.

Study Overview

• Status: Completed
• Conditions: Insomnia; Sleep; Obstructive Sleep Apnea
• Intervention / Treatment: Behavioral: Behavioral Intervention

Detailed Description

Disturbed sleep, most notably insomnia and obstructive sleep apnea (OSA), is highly prevalent and associated with increased risk for elevated blood pressure (BP) and cardiovascular disease. Unfortunately, despite the substantial public health burden of disturbed sleep, standard treatments are often limited by poor adherence, inadequate availability, and/or significant side effects. As such, identification of alternative approaches to mitigate disturbed sleep is greatly needed. In contrast to increasing engagement in exercise, we propose that reducing sedentary behavior (SED), or time spent sitting, is a novel and feasible approach to reduce sleep disturbance. We also propose that the presence of disturbed sleep during the intervention could blunt the adherence to attempted SED reduction and impact its cardiovascular health benefits. Therefore, the goal of this ancillary study is to test the hypotheses that SED reduction will improve sleep and that the presence of baseline sleep disturbance will reduce the effectiveness of SED reduction efforts. We will test this hypothesis by adding comprehensive sleep assessments to an ongoing randomized clinical trial (NCT03307343) that is examining the effect of SED reduction on BP. In this parent trial, 300 desk workers with elevated BP are randomized to a 3-month multicomponent behavioral intervention aimed at replacing 2-4 hr/day of SED with light-intensity activity or a 3-month no-contact control condition.

Anticipating the ability to enroll 150 participants from the remaining sample of the parent trial (estimated N~210), we will assess sleep at baseline and post-intervention using 7 nights of wrist-worn actigraphy and 1 night of home-based polysomnography (PSG), yielding objective measures of sleep quality (WASO), total sleep time (TST), OSA severity (apnea-hypopnea index [AHI]), and sleep depth (slow-wave sleep [SWS]. These data will allow us to efficiently address the following specific aims:

Aim 1: To evaluate the effect of a 3-month SED reduction intervention on objective measures of sleep quality, depth, duration, and OSA severity.

Hypothesis: Participants randomized to the SED reduction intervention will have greater reduction than control participants in actigraphy-assessed WASO (primary outcome [hypothesis 1.1]), PSG-assessed AHI and SWS, and greater increase in actigraphy-assessed TST (secondary outcomes [hypothesis 1.2]).

Aim 2: To examine the effect of baseline disturbed sleep on SED reduction and BP improvement.

Hypothesis: Intervention-induced reductions in SED (hypothesis 2.1) and BP (hypothesis 2.2) will be smaller among individuals with disturbed sleep (e.g., elevated WASO or AHI) at baseline.

• Study Type: Interventional
• Enrollment (Actual): 176
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15261
      • University of Pittsburgh Physical Activity and Weight Management Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age 21-65 years
2. SBP of 120-159 mmHg or DBP of 80-99 mmHg
3. Physically inactive or insufficiently active (i.e., not meeting current aerobic MVPA recommendations [≥150 min/wk])
4. Currently perform deskwork for ≥ 20 hr/wk at a desk compatible with a sit-stand desk attachment
5. Employment within 25-mi radius of University of Pittsburgh
6. Stable employment (≥ 3 mo at current job, plan to be in current job for at least the next 3 mo)
7. Supervisor approval to join intervention
8. Possession of cellular phone able to receive text messages

Exclusion Criteria:

1. SBP ≥ 160 mmHg or DBP ≥ 100 mmHg
2. Use of anti-hypertensive or glucose-controlling medication
3. Comorbid condition that would limit ability to reduce sedentary behavior (e.g., musculoskeletal condition)
4. History of ischemic heart disease, chronic heart failure, stroke, or chronic kidney disease
5. Inability to obtain consent from primary care provider/physician to participate
6. Current use of a sit-stand desk or sedentary behavior prompting device
7. Current enrollment in a weight loss or exercise program, recent (< 1 yr) or planned bariatric surgery
8. Plans to be away from work for an extended period (>1 wk) during the study period
9. Current or recent (within last 6 mo) pregnancy; current or recent (within last 3 mo) breastfeeding
10. Undiagnosed severe OSA (AHI ≥ 30) or insomnia (ISI ≥ 22)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Behavioral Intervention; The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.	Behavioral: Behavioral Intervention; The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
No Intervention: Control Condition; Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline actigraphic wake after sleep onset (WASO) at 3 months	Primary outcome for Aim 1: actigraphy-assessed wake after sleep onset, averaged over 7 nights	3 months
Change from baseline activPAL-assessed sedentary behavior (SED) at 3 months	Primary outcome for Aim 2: SED, assessed via activPAL inclinometer, averaged over 7 days	3 months
Change from baseline resting systolic blood pressure (SBP) at 3 months	Primary outcome for Aim 2: resting SBP, measured via oscillometric device following a 10-minute rest averaged over two separate occasions	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline total sleep time (TST) at 3 months	Secondary outcome for Aim 1: actigraphy-assessed TST, averaged over 7 nights	3 months
Change from baseline apnea-hypopnea index (AHI) at 3 months	Secondary outcome for Aim 1: polysomnography-assessed AHI, assessed over 1 night of home-based recording	3 months
Change from baseline slow-wave sleep (SWS) at 3 months	Secondary outcome for Aim 1: polysomnography-assessed slow-wave sleep, assessed over 1 night of home-based recording	3 months
Change from baseline 24-hour blood pressure at 3 months	Secondary outcome for Aim 2: blood pressure, assessed by an ambulatory monitor during a workday and overnight for 24 hours total	3 months
Change from baseline pulse wave velocity (PWV) at 3 months	Secondary outcome for Aim 2: carotid-femoral and carotid-radial PWV, assessed via tonometry following a 10-minute rest	3 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline self-reported sleep patterns at 3 months	Self-reported sleep patterns will be assessed via a daily diary; mean and measures of variability will be obtained from 7 nights of data	3 months
Change from baseline Epworth Sleepiness Scale (ESS) scores at 3 months	The ESS, a measure of daytime sleepiness, will be administered at baseline and 3 months; total score will be used	3 months
Change from baseline Insomnia Severity Index (ISI) scores at 3 months	The ISI, a measure of insomnia symptom severity, will be administered at baseline and 3 months; total score will be used	3 months
Change from baseline Functional Outcomes of Sleep Questionnaire (FOSQ) scores at 3 months	The 10-item version of the FOSQ, a measure of daytime dysfunction due to poor sleep, will be administered at baseline and 3 months; total score will be used	3 months
Change from baseline PROMIS Sleep-related Impairment scale scores at 3 months	The PROMIS (Patient-Reported Outcomes Measurement Information System) Sleep-related Impairment Scale, a measure of daytime impairment, will be administered at baseline and 3 months; total score will be used	3 months
Change from baseline Pittsburgh Sleep Quality Index (PSQI) scores at 3 months	PSQI will be administered at baseline and 3 months; global score and 3 factors (sleep efficiency, perceived sleep quality, daily disturbances) will be used	3 months
Change from baseline actigraphic sleep patterns at 3 months	Actigraphic sleep patterns will be assessed with the Actiwatch Spectrum Plus; mean and measures of variability will be obtained from 7 nights of data	3 months
Change from baseline polysomnography (PSG)-assessed sleep patterns at 3 months	Polysomnography will be performed in the participant's home at baseline and 3 months	3 months
Change from baseline weight at 3 months	Weight will be measured by digital scale at baseline and 3 months	3 months
Change from baseline glucose at 3 months	Glucose will be measured from a fasting blood draw at baseline and 3 months	3 months
Change from baseline insulin at 3 months	Insulin will be measured from a fasting blood draw at baseline and 3 months	3 months
Change from baseline accelerometer-assessed physical activity at 3 months	Physical activity will be assessed via waist-worn ActiGraph GT3X accelerometer at baseline and 3 months	3 months

Collaborators and Investigators

• Sponsor: University of Pittsburgh
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
• Investigators: Principal Investigator: Christopher E Kline, PhD, Assistant professor

Study record dates

Study Major Dates

• Study Start (Actual): May 6, 2019
• Primary Completion (Actual): December 30, 2022
• Study Completion (Actual): December 30, 2022

Study Registration Dates

• First Submitted: May 8, 2019
• First Submitted That Met QC Criteria: May 9, 2019
• First Posted (Actual): May 10, 2019

Study Record Updates

• Last Update Posted (Actual): July 7, 2023
• Last Update Submitted That Met QC Criteria: July 6, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: physical activity; blood pressure; sedentary behavior
• Additional Relevant MeSH Terms: Nervous System Diseases; Respiratory Tract Diseases; Apnea; Respiration Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Sleep Apnea Syndromes; Sleep Apnea, Obstructive
• Other Study ID Numbers: STUDY18120122; R01HL147610 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Individual deidentified data that are relevant to the primary aims of the study will be provided to external investigators along with a relevant data dictionary.
• IPD Sharing Time Frame: Beginning 1 year following peer-reviewed publication of research questions outlined in grant and ending 5 years following publication of study results
• IPD Sharing Access Criteria: Data access will be provided to external researchers who provide a methodologically sound proposal for secondary data analysis that is approved by the investigators of the study. Proposals should be directed to the study PI.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No